X0202 SCHEDULE 13G/A 0001104659-26-016662 0001940272 XXXXXXXX LIVE 1 Common Stock, par value $0.001 per share 06/30/2026 0001636651 Ovid Therapeutics Inc. 690469101 441 Ninth Avenue 14th Floor New York NY 10001 Rule 13d-1(b) ADAR1 Capital Management, LLC b TX 0.00 9559979.00 0.00 9559979.00 9559979.00 N 5.1 IA OO Includes (i) 6,980,088 shares of common stock, par value $0.001 per share ("Common Stock") held by ADAR1 Partners, LP, (ii) 435,032 shares of Common Stock held by Spearhead Insurance Solutions IDF, LLC, (iii) 2,359 shares of Common Stock held by other separately managed accounts and (iv) 2,142,500 shares of Common Stock underlying warrants held by ADAR1 Partners, LP, the exchange and exercise of which are subject to 9.99% beneficial ownership limitations. As the investment manager of ADAR1 Partners, LP, as the sub-advisor of Spearhead Insurance Solutions IDF, LLC and as the manager of the separately managed accounts referenced above, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC and the separately managed accounts. Based on 184,755,735 shares of Common Stock of Ovid Therapeutics Inc (the "Issuer") outstanding as of June 30, 2026, reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 13, 2026. ADAR1 Capital Management GP, LLC b TX 0.00 9122588.00 0.00 9122588.00 9122588.00 N 4.9 OO Includes (i) 6,980,088 shares of Common Stock held by ADAR1 Partners, LP and (ii) 2,142,500 shares of Common Stock underlying warrants held by ADAR1 Partners, LP, the exchange and exercise of which are subject to 9.99% beneficial ownership limitations. As the general partner of ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP. Based on 184,755,735 shares of Common Stock of the Issuer outstanding as of June 30, 2026, reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 13, 2026. Daniel Schneeberger b V8 0.00 9559979.00 0.00 9559979.00 9559979.00 N 5.1 HC IN Includes (i) 6,980,088 shares of Common Stock held by ADAR1 Partners, LP, (ii) 435,032 shares of Common Stock held by Spearhead Insurance Solutions IDF, LLC, (iii) 2,359 shares of Common Stock held by other separately managed accounts and (iv) 2,142,500 shares of Common Stock underlying warrants held by ADAR1 Partners, LP, the exchange and exercise of which are subject to 9.99% beneficial ownership limitations. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC and the separately managed accounts referenced above. Based on 184,755,735 shares of Common Stock of the Issuer outstanding as of June 30, 2026, reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 13, 2026. Ovid Therapeutics Inc. 441 Ninth Avenue, 14th Floor, New York, NY 10001 This Schedule is being filed on behalf of each of the following persons (each, a "Reporting Person" and collectively, the "Reporting Persons"): (i) ADAR1 Capital Management, LLC ("ADAR1 Capital Management"); (ii) ADAR1 Capital Management GP, LLC ("ADAR1 General Partner"); and (iii) Daniel Schneeberger ("Mr. Schneeberger"). Pursuant to Item 5 below, this filing is an exit filing solely for ADAR1 General Partner. The address of the principal business office of each of the Reporting Persons is 3503 Wild Cherry Drive, Building 9, Austin, Texas 78738. (i) ADAR1 Capital Management is a Texas limited liability company; (ii) ADAR1 General Partner is a Texas limited liability company; and (iii) Mr. Schneeberger is a citizen of Switzerland. N IA HC The information contained on the cover pages of this Schedule 13G is incorporated herein by reference. The information contained on the cover pages of this Schedule 13G is incorporated herein by reference. The information contained on the cover pages of this Schedule 13G is incorporated herein by reference. The information contained on the cover pages of this Schedule 13G is incorporated herein by reference. The information contained on the cover pages of this Schedule 13G is incorporated herein by reference. The information contained on the cover pages of this Schedule 13G is incorporated herein by reference. N Y Y N Mr. Schneeberger is filing this Schedule 13G as a control person in respect of shares beneficially owned by ADAR1 Capital Management, an investment adviser as described in SS 240.13d-1(b)(1)(ii)(E). Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. ADAR1 Capital Management, LLC /s/ Daniel Schneeberger 08/14/2026 ADAR1 Capital Management GP, LLC /s/ Daniel Schneeberger 08/14/2026 Daniel Schneeberger /s/ Daniel Schneeberger 08/14/2026